Gilmore O’Neill: I think when you said previous years, I think you meant previous months and weeks.
Baisong Mei: Last several months as well, yes sir.
Gilmore O’Neill: Yes. Thank you. And a lot of enthusiasm and excitement from patients and investigators when we disclosed the initial 301 data in December. Thanks very much.
Rick Bienkowski: Great, thank you.
Operator: Our next question is from Joel Beatty with Baird. Please proceed.
Unidentified Analyst: Hi thank you so much for taking the questions, it is dialing-in and for Joel. We were hoping you can provide an update as it relates to the IP dynamics surrounding CRISPR/Cas9, and your IP there in light of the February 2022 decision by the USPTO. I ask as your competitor, CRISPR and Vertex is looking to commercialize CTX001 as aCAS9 based therapy for sickle cell and beta thalassemia in late 2023, early 2024. And I was wondering if you had any thoughts as it relates to the time course of potential, I guess settlements or any litigation surrounding IP of that CAS9 portfolio? Thank you so much.
Gilmore O’Neill: Thanks very much, Jack for the question. And obviously, we were very happy that the broads IP was upheld by the PTAB last February. I think, the key thing is that this is a very exciting time and we are delighted for patients. This is an exciting time, because we are looking potentially at the first approval for a CRISPR based medicine for patients with very serious diseases. Obviously, we look to a negotiated agreement to enable our — the continuing advance of the technology, and we will be updating you on the details of that an appropriate time.
Unidentified Analyst: Thanks so much.
Gilmore O’Neill: Thank you.
Operator: Our next question is from Jay Olson with Oppenheimer. Please proceed.
Jay Olson: Hey thank you for the update and thanks for taking the questions. Can you talk about any feedback that you received from your independent data monitoring community and their latest review of the RUBY trial? And then a second question, as a result of your portfolio reprioritization process, are there any implications for operating expenses or your capital allocation strategy this year? Thank you.
Gilmore O’Neill: Thank you very much. Baisong, do you want to talk about the IDMC feedback and the release for parallel dosing?
Baisong Mei: Yes, sure. Thanks, Jay, for the question. Yes. The IDMC had reviewed the data from the two Sentinel patients, and they agreed for continued and dosing and parallel dosing of the patients.
Gilmore O’Neill: Thanks very much, Baisong. And then with regard to the implications for OPEX and capital allocation, I’m going to pass that to Michelle.
Michelle Robertson: Great. Hi, Jay. So with the refocus strategy, we were able to extend our cash runway into 2025. We don’t give out guidance on expenses, but obviously you can back into that. Given that our cash balance was 437 million at the end of the year, and we will continue to invest in EDIT-301, both of the clinical trials continue to invest in CMC, and then obviously in our advanced technology and further in-vivo platform.
Jay Olson: Great, thank you very much. Thanks very much Michelle. Thanks.
Operator: Our next question is from Brian Cheng with JP Morgan. Please proceed.
